Amarin announced the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza capsules to Vascepa capsules. During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. The company said, "We have heard many anecdotal reports of the success physicians have had with Vascepa since its launch last year. The results published by Dr. Castaldo provide important hypothesis generating evidence of the potential benefit of treating patients with EPA-only Vascepa that requires additional study for substantiation. These real-world results are exciting and encouraging when considered alongside the findings of the pivotal Phase 3 studies conducted with Vascepa, which demonstrated that EPA-only Vascepa reduced TG levels without increasing levels of bad cholesterol, LDL-C, in patients with high and very high triglyceride levels."